CTNNB1 Activating Mutation

CI-VAR-00000179Explore in graph →CIViC 1296

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Desmoid Fibromatosis1
APC Mutation OR CTNNB1 Activating Mutation	Nirogacestat	Predictive	A	Supports Sensitivity Response	2	submitted	EID12023 In a phase 3 trial (NCT03785964) involving 142 adults with progressing desmoid tumors, the gamma-secretase inhibitor nirogacestat demonstrated a significant progression-free survival benefit compared … (full text at CIViC) PMID 36884323 · Gounder et al., 2023 · Open in CIViC	civic
Melanoma1
CTNNB1 Activating Mutation	Anti-CTLA-4 Monoclonal Antibody + Anti-PD-L1 Monoclonal AntibodySubstitutes	Predictive	D	Supports Resistance	4	accepted	EID2988 Activation of melanoma-cell-intrinsic WNT/β-catenin signalling pathway contributes to a lack of T-cell infiltration in melanoma. Molecular analysis of human metastatic melanoma samples revealed a corr…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.